By Josh Beckerman
Shares of TransCode Therapeutics rose 9.4% Tuesday after the company’s chief executive and chief financial officer reported stock purchases.
The stock recently traded at 50 cents and is down about 96% this year.
According to filings Monday, TransCode Chief Executive Michael Dudley bought 98,000 shares and Chief Financial Officer Thomas A. Fitzgerald bought 49,350 shares.
TransCode is developing cancer drugs.
Write to Josh Beckerman at [email protected]
Read the full article here